LLY:NYE-Eli Lilly and Company

EQUITY | Drug Manufacturers | New York Stock Exchange

Last Closing Price

USD 85.29

Change

-1.69 (-1.94)%

Market Cap

USD 93.91B

Volume

4.88M

Yahoo Analyst Target

USD 92.14 (8.03%)

STA Analyst Target

USD 89.00 (4.35%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Eli Lilly and Co is a drug manufacturing company. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-16 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
JNJ Johnson & Johnson

+1.10 (+0.75%)

USD 394.54B
PFE Pfizer Inc.

+0.06 (+0.16%)

USD 218.16B
NVS Novartis AG

+0.08 (+0.09%)

USD 203.20B
MRK Merck & Company Inc. (new)

+3.41 (+5.81%)

USD 169.11B
ABBV AbbVie Inc.

+2.15 (+2.14%)

USD 163.62B
SNY Sanofi American Depositary Sha..

+0.13 (+0.29%)

USD 113.03B
ABT Abbott Laboratories

-0.40 (-0.68%)

USD 101.72B
BMY Bristol-Myers Squibb Company

-2.89 (-4.60%)

USD 98.07B
GSK GlaxoSmithKline PLC

+0.42 (+1.12%)

USD 94.00B
AZN Astrazeneca PLC

-0.66 (-1.85%)

USD 88.61B

ETFs Containing LLY

IHE iShares U.S. Pharmaceutic.. 5.80 % 0.44 %

-0.97 (-1.05%)

USD 0.57B
PJP PowerShares Dynamic Pharm.. 4.87 % 0.56 %

-0.32 (-1.05%)

USD 0.66B
HHL:CA Healthcare Leaders Income.. 4.81 % 1.37 %

-0.04 (-1.05%)

CAD 0.26B
XPH SPDR S&P Pharmaceuticals 4.64 % 0.35 %

-0.45 (-1.05%)

USD 0.41B
FTXH First Trust Nasdaq Pharma.. 3.87 % 0.60 %

-0.24 (-1.05%)

USD 2.22M
PILL Direxion Daily Pharmaceut.. 1.76 % 0.00 %

-0.33 (-1.05%)

USD 3.19M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.98% 17% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.98% 17% F 44% F
Trailing 12 Months  
Capital Gain 10.19% 48% F 55% F
Dividend Return 2.02% 29% F 30% F
Total Return 12.21% 48% F 52% F
Trailing 5 Years  
Capital Gain 61.14% 61% D- 69% D+
Dividend Return 17.99% 47% F 55% F
Total Return 79.12% 61% D- 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 12.89% 78% C+ 82% B-
Dividend Return 15.92% 78% C+ 83% B
Total Return 3.03% 53% F 55% F
Risk Return Profile  
Volatility (Standard Deviation) 15.06% 74% C 51% F
Risk Adjusted Return 105.69% 91% A- 82% B-
Market Capitalization 73.27B 59% F 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.30 22% F 16% F
Price/Book Ratio 6.66 26% F 12% F
Price / Cash Flow Ratio 4.11 57% F 31% F
Price/Free Cash Flow Ratio 24.72 30% F 27% F
Management Effectiveness  
Return on Equity 15.60% 52% F 76% C
Return on Invested Capital 15.56% 70% C- 77% C+
Return on Assets 5.55% 65% D 74% C
Debt to Equity Ratio 81.00% 45% F 48% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.